Nkg2d-based Car-t In R/r Aml And Mds

2020 2:21
Synopsis
CYAD-01 is a natural killer group 2D (NKG2D)-based CAR T-cell product. David Sallman, MD, H. Lee Moffitt Cancer Center ...

You Might Also Like

CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS 2:29
Cycle-1: Next Generation Nkg2d-based Car T-cells In Aml/mds
2022
NKG2D CARs for R/R AML and MDS 1:47
Nkg2d Cars For R/r Aml And Mds
2020
Insights into NKG2D-targeting CAR-T cells in R/R AML 1:30
Insights Into Nkg2d-targeting Car-t Cells In R/r Aml
2024
NKG2D CAR-T cell therapy in AML/MDS 2:00
Nkg2d Car-t Cell Therapy In Aml/mds
2022
THINK trial: Phase I results for NKG2D CAR-T therapy in AML 4:03
Think Trial: Phase I Results For Nkg2d Car-t Therapy In Aml
2019
David Sallman | ASH 2018 | Key results of the phase I THINK trial of NKG2D CAR-T therapy in R/R AML 3:33
David Sallman | Ash 2018 | Key Results Of The Phase I Think ...
2019
NKG2D-based CAR T-cells in solid tumors 1:46
Nkg2d-based Car T-cells In Solid Tumors
2026
Allogeneic CAR-NK cell therapy in R/R AML/MDS 3:18
Allogeneic Car-nk Cell Therapy In R/r Aml/mds
2022
Hurdles to CAR-T therapy for MDS & AML: T-cell fitness & lack of a uniform target antigen 1:16
Hurdles To Car-t Therapy For Mds & Aml: T-cell Fitness & Lac...
2024
Advanced cell therapy based on the chimeric receptor NKG2D: the NK-T cell approach 19:40
Advanced Cell Therapy Based On The Chimeric Receptor Nkg2d: ...
2021
Potential for CAR T-Cell Therapy for R/R AML 3:59
Potential For Car T-cell Therapy For R/r Aml
2019
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.